Plerixafor , 2mMinWater , 110078-46-1
CAS NO.：110078-46-1
Empirical Formula: C28H54N8
Molecular Weight: 502.78
MDL number: MFCD05662218
EINECS: 1592732-453-0
| Pack Size | Price | Stock | Quantity |
| 1ml | RMB159.20 | In Stock |
|
| others | Enquire |
PRODUCT Properties
| Melting point: | 122-125°C |
| Boiling point: | 657.5±55.0 °C(Predicted) |
| Density | 0.962 |
| storage temp. | Keep in dark place,Inert atmosphere,2-8°C |
| solubility | Methanol (Slightly), Water (Slightly) |
| form | Solid |
| pka | 10.60±0.20(Predicted) |
| color | White to Pale Beige |
| Stability: | Hygroscopic |
| CAS DataBase Reference | 110078-46-1 |
Description and Uses
Autologous hematopoietic stem cell (HSC) transplantation, a standard
treatment for hematological malignancies, such as non-Hodgkin’s lymphoma or multiple myeloma, involves collection of HSCs from the
patient, chemo- or radiotherapy of the patient to eliminate malignant cells,
and retransplantation of the stored HSCs.
Plerixafor is a potent antagonist of the CXCR4 chemokine receptor and a first-in-class drug for stem cell mobilization. CXCR4
is specific for stromal-derived-factor-1 (SDF-1), a molecule endowed with
potent chemotactic activity forlymphocytes. Because the interaction between
SDF-1 and CXCR4 plays an important role in holding HSCs in the bone
marrow, drugs that block the activity of CXCR4 receptor are capable of
mobilizing HSCs into the bloodstream. In vitro, plerixafor potently blocks
SDF-1 binding of CXCR4 and inhibits SDF-1-induced calcium flux
(IC50 = 0.01-0.13 mg/mL) and chemotaxis (IC50 = 0.13 mg/mL) in several
different cell types.
Plerixafor, in combination with G-CSF, is specifically
indicated to mobilize HSCs to the peripheral blood for collection and subsequent autologous transplantation in patients with non-Hodgkin’s lymphoma and multiple myeloma.
Plerixafor is a hematopoietic stem cell (HSC) mobilizer that inhibits the CXCR4 chemokine receptor and blocks binding of its ligand, stromal cell-derived factor-1-α (SDF-1-α). This agent was approved on Dec. 15, 2008, as treatment in combination with granulocyte-colony stimulating factor (G-CSF) to mobilize HSCs to the peripheral blood for collection and subsequent autologous transplantation in patients with non-Hodgkin''s lymphoma (NHL) and multiple myeloma (MM). Selective CXCR4 antagonist.
Safety
| Symbol(GHS) |  GHS07 |
| Signal word | Warning |
| Hazard statements | H319-H315 |
| Precautionary statements | P264-P280-P302+P352-P321-P332+P313-P362-P264-P280-P305+P351+P338-P337+P313P |
| HS Code | 29339900 |
